Bengaluru-based startup Ayati Devices secures INR 15 crore in pre-Series A funding, aiming to scale its integrated diagnostic tools for diabetic foot and vascular care across international markets amid rising diabetes prevalence in India.
Ayati Devices, a Bengaluru-based medical technology company, has raised INR 15 crore in a pre-Series A round led by Inflexor Ventures, its first institutional backing. The company said the capital will be used to push its diagnostic tools into wider commercial use, expand its reach in India and overseas, and strengthen manufacturing, research, regulatory work and artificial intelligence development. Founded by Nishant Kathpal and incubated at IITB-SINE, Ayati is building what it describes as an integrated platform for diabetic foot and vascular care.
The timing matters. India is facing a steep diabetes burden, with more than 90 million people living with the condition, while many cases of nerve damage and poor circulation go unnoticed until serious complications emerge. The company says more than 50,000 lower-limb amputations are carried out in India each year, many of them avoidable with earlier screening and better access to diagnostics.
Ayati’s portfolio is aimed at that gap. Its devices include Vibrasense for neuropathy screening, Vibrasense+T for broader nerve assessment, Vasosense for peripheral artery disease and Angiocam for tissue perfusion imaging. The company also offers the PODIA Trolley, a pay-per-test screening station designed to lower the entry barrier for clinics and hospitals that cannot afford heavy upfront investment. Ayati says its Ayati Foot Labs platform links assessment of neuropathy, blood flow, microcirculation and plantar pressure into a single workflow.
The company says its systems already have regulatory clearances in India, the US, Europe, Sri Lanka, Malaysia and the UAE. It claims deployments in more than 30 countries and says more than 10,000 devices are in use, supported by distributors and clinical installations at hospitals including Medicover and Aster. That footprint suggests the business is trying to move beyond a single-device play and into a broader preventive-care platform.
Ayati said the new funding will help commercialise Angiocam, expand sales and distribution, deepen its intellectual property base and add staff across engineering, clinical affairs, regulation and international business development. The company is targeting Europe, the US, the Middle East, South East Asia, Australia and Latin America, while also weighing direct operations in selected markets as demand grows. It wants to position preventive diagnostics closer to primary care and community screening, rather than leaving them largely confined to specialist centres.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
